BioCentury
ARTICLE | Company News

Biohaven gets rights to AZ's myeloperoxidase inhibitor

September 7, 2018 5:54 PM UTC

AstraZeneca plc (NYSE:AZN; LSE:AZN) granted the Biohaven Therapeutics Ltd. subsidiary of Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) exclusive, worldwide development and commercialization rights to BHV3241 (AZD3241). Biohaven has rights to all indications except cardiovascular disease.

AZ will receive an upfront payment and shares in Biohaven, and is eligible for milestones plus double-digit royalties. Financial terms were not disclosed...